Cannabis Science Provides Physician’s Documentation That Confirms Successful Treatment of Skin Cancer
DENVER--(BUSINESS WIRE)--Cannabis Science, Inc. (OTCBB: CBIS), US biotech company developing pharmaceutical cannabis products. On March 9, 2011 Cannabis Science announced that we would follow up our press release with medical documentation regarding the effectiveness of our cannabis extracts for treating skin cancer as was documented photographically in our earlier press release of February 22, 2011. We are pleased to announce that we have physician’s documentation that confirms the successful treatment of basal cell carcinoma that resulted from the application of a topical cannabis extract.
Please visit www.cannabisscience.com to view the “Breaking News” of the successful results and images of the self-administered cancer treatments along with the physician's documentation after 4pm EST., today.
Currently, there is a tremendous amount of controversy with respect to the effects that cannabinoids have on cancers. Endocannabinoids, phytocannabinoids, and synthetic cannabinoids have demonstrated cancer killing and anti-metastatic properties in tissue culture and in animal models. While formal, proper, FDA approved clinical trials that would prove or disprove the therapeutic potential of cannabis extracts for treating cancers; trials have not been carried out. Nevertheless, a significant number of anecdotal observations have accumulated that suggest people suffering from a variety of cancers appear to have been cured by ingesting what is known as “Rick Simpson's hemp oil”.
There is widespread ignorance regarding the endocannabinoid system by medical professionals and laymen alike. The first hint that an endocannabinoid system existed resulted from an experiment published in 1988. Because of the endemic political and social bias against medical cannabis, nurtured by decades of misinformation, Cannabis Science has chosen a path that we feel will have the greatest probability of successfully traversing the FDA approval process. Our initial test product will only be topical, and will be formulated to reduce any internal consumption and thus reduce any abuse potential. With these considerations in mind, we will initially seek FDA approval for topically applied cannabis extracts for the treatment of basal cell carcinoma, a common form of skin cancer.
According to the National Cancer Institute ( http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001827/), basal cell carcinoma is the most frequently occurring cancer in the United States. Because of the horrific impact that cancer in general has on so many people worldwide, Cannabis Science has decided to make basal cell carcinoma its first target for clinical trial.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.